Tracers / [225Ac]Ac-PSMA-I&T
[225Ac]Ac-PSMA-I&T
Also written as PSMA I&T; [Ac-225]Ac-PSMA-I&T; PSMA-I&T
- Radionuclide
- Ac-225 t½ 14284.8 min
- Modality
- Therapy
- Production route
- —
- Stage
- phase I clinical trial (planned/dose escalation)
- Syntheses indexed
- 7
What it is
- Compound class
- PSMA-targeting peptide (urea-based ligand), DOTA-conjugated, radiolabeled with Ac-225
- Target / mechanism
- Targets prostate-specific membrane antigen (PSMA) PMID 41043997
- Clinical application
- Targeted alpha therapy for metastatic castration-resistant prostate cancer (mCRPC) PMID 34068206
- Theranostic pair
- <a href="/tracers/ga68-psma-it/">ga68-psma-it</a>
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | — | — | — | PSMA I&T piCHEM, Raaba-Grambach, Austria | 42481872 2026 EJNMMI Radiopharm Chem a solid 225Ac sample (40–60 MBq) was dissolved within 30 min by using 30 µL of 0.1 M HCl at room temperature |
| — | — | — | — | — | — | 41043997 2025 J Nucl Med |
| — | — | — | — | — | — | 38512484 2024 Eur J Nucl Med Mol Imaging |
| — | — | — | — | — | — | 36629878 2023 Eur J Nucl Med Mol Imaging |
| Modular-Lab EAZY Eckert & Ziegler | vendor cassette | SPE | 80-90% | >95% | PSMA-I&T piCHEM, Raaba-Grambach, Austria | 34358076 2021 Pharmaceuticals (Basel) The Modular-Lab EAZY module (GTL) with software Modular-Lab v6.2 was obtained from Eckert & Ziegler (Berlin, Germany). — final radiochemical yields of 80–90% for the 225Ac-labeled peptides |
| Manual synthesis Biotage | custom manifold | SPE | >95% | >90% | PSMA-I&T Scintomics, Fürstenfeldbruck, Germany | 34068206 2021 Pharmaceutics a specific microwave (Biotage Initiator+, Biotage, Uppsala, Sweden) was used for labeling — radiochemical yield >95% |
| — | — | — | — | — | — | 33008928 2021 J Nucl Med |
Need this precursor?We can point you to suppliers for [225Ac]Ac-PSMA-I&T, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 5 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Diagnostic pair signal at discovery: YES - Ga-68. Compound class inferred from precursor name (not stated outright) -- PMID 34358076: 'PSMA-I&T'. Stage set/updated at stage 23 from PMID 34068206: 'The start of the phase I dose escalation study is planned in the near future.'.